Acadia Pharmaceuticals (ACAD)
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business